PUMA BIOTECHNOLOGY, INC.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | OTHER INFORMATION |
|---|
Trading Plans
During the fiscal quarter ended* March 31, 2025,our directors and officers (as defined in Rule16a*-1(f) under the Exchange Act) who adopted or terminated contracts, instructions, written plans or arrangements for the purchase or sale of our securities are set forth in the table below:
| Trading Arrangement | Total Shares of Common | |||||
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Allison Dorval, Board Member | Adopt | March 12, 2025 | X | Up to 23,220 shares | June 18, 2026 | |
| Alessandra Cesano, Board Member | Adopt | March 11, 2025 | X | Up to 39,150 shares | December 18, 2025 | |
| Jay Moyes, Board Member | Adopt | March 12, 2025 | X | Up to 44,000 shares | June 16, 2026 | |
| Adrian Senderowicz, Board Member | Adopt | March 12, 2025 | X | Up to 54,000 shares | June 26, 2026 | |
| Brian Stuglik, Board Member | Adopt | March 12, 2025 | X | Up to 16,200 shares | June 26, 2026 | |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
Not intended to satisfy the affirmative defense of Rule10b5-1(c)
36
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.